Scisparc Ltd (SPRC) - Total Assets
Based on the latest financial reports, Scisparc Ltd (SPRC) holds total assets worth $5.14 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Scisparc Ltd net assets for net asset value and shareholders' equity analysis.
Scisparc Ltd - Total Assets Trend (2006–2024)
This chart illustrates how Scisparc Ltd's total assets have evolved over time, based on quarterly financial data.
Scisparc Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Scisparc Ltd's total assets of $5.14 Million consist of 72.5% current assets and 27.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.9% |
| Accounts Receivable | $4.96 Million | 48.0% |
| Inventory | $113.00K | 1.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.48 Million | 14.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Scisparc Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Scisparc Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scisparc Ltd's current assets represent 72.5% of total assets in 2024, a decrease from 98.3% in 2006.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2024, down from 50.6% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 48.0% of total assets.
Scisparc Ltd Competitors by Total Assets
Key competitors of Scisparc Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Crispr Therapeutics AG
NASDAQ:CRSP
|
USA | $2.73 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Scisparc Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.55 | 1.86 | 2.25 |
| Quick Ratio | 0.52 | 1.63 | 2.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.29 Million | $1.56 Million | $1.42 Million |
Scisparc Ltd - Advanced Valuation Insights
This section examines the relationship between Scisparc Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.12 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | -7.5% |
| Total Assets | $10.35 Million |
| Market Capitalization | $3.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scisparc Ltd's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scisparc Ltd's assets decreased by 7.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scisparc Ltd (2006–2024)
The table below shows the annual total assets of Scisparc Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $10.35 Million | -7.47% |
| 2023-12-31 | $11.18 Million | +5.44% |
| 2022-12-31 | $10.61 Million | +6.95% |
| 2021-12-31 | $9.92 Million | +287.19% |
| 2020-12-31 | $2.56 Million | +121.92% |
| 2019-12-31 | $1.15 Million | -74.69% |
| 2018-12-31 | $4.56 Million | -52.33% |
| 2017-12-31 | $9.57 Million | +668.52% |
| 2016-12-31 | $1.24 Million | -25.26% |
| 2015-12-31 | $1.67 Million | +537.64% |
| 2014-12-31 | $261.18K | -84.56% |
| 2013-12-31 | $1.69 Million | +54.83% |
| 2012-12-31 | $1.09 Million | -75.33% |
| 2011-12-31 | $4.43 Million | -55.63% |
| 2010-12-31 | $9.98 Million | -18.32% |
| 2009-12-31 | $12.22 Million | +22.00% |
| 2008-12-31 | $10.01 Million | -34.18% |
| 2007-12-31 | $15.22 Million | +35.65% |
| 2006-12-31 | $11.22 Million | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more